Loading...
Market
Story
NHS Blocks Second Alzheimer’s Drug, Donanemab, Over Cost Concerns
Oct 23, 2024, 07:40 AM
Eli Lilly's Alzheimer's drug donanemab has been rejected for use on the NHS in England due to cost concerns. Despite being deemed safe by regulators and considered the most effective treatment yet for Alzheimer's disease, the National Institute for Health and Care Excellence (NICE) has concluded that donanemab does not currently demonstrate value for money. The drug, which has been shown to slow the progression of the disease by four to seven months in clinical trials, will not be available to patients through the NHS pending further evidence on its clinical and cost-effectiveness. This marks the second Alzheimer's drug to be blocked by the NHS over high costs. NICE announced the decision on Wednesday and has opened a consultation on its draft guidance.
View original story
Similar markets
Yes • 50%
No • 50%
Approved for preventive use • 25%
Approved with restrictions • 25%
Rejected • 25%
No decision • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%